We have previously reported that centrally acting non-
narcotic antitussives inhibited
G protein-coupled inwardly rectifying
potassium (GIRK) channel-activated currents, and that the
antitussives had multiple pharmacological actions on various models of intractable
brain diseases in rodents. In this study, the question of whether these
antitussives inhibit
drug-induced hyperactivity in mice was investigated.
Antitussives, such as
cloperastine and
tipepidine, at
cough suppressant doses, inhibited an increase in ambulation of mice neonatally treated with
6-hydroxydopamine. In addition, all
antitussives studied inhibited an increase in
methamphetamine-induced hyperactivity in mice.
Methylphenidate, which is used for treatment of
ADHD, inhibited 6-hydroxydopamine-lesion-induced, but not
methamphetamine-induced, hyperactivity in mice. By the rota-rod test, the drugs had little effect on motor coordination of the hyperactive mice. Significant correlation was found between the ameliorating effects of
antitussives on
methamphetamine-induced hyperactivity and their inhibitory actions on GIRK channel currents (coefficient factor, 0.998). Furthermore,
tertiapin, a GIRK channel blocker, prevented an increase in
methamphetamine-induced hyperactivity of mice. These results demonstrated that
antitussive drugs (
cloperastine,
tipepidine and
caramiphen) possessing inhibitory action on GIRK channels inhibit
drug-induced hyperactivity in mice, suggesting that such
antitussives may potentially be therapeutic for patients with
ADHD.